Rewriting Life

Born-Again Heart

Hydra BioSciences’ drugs could rejuvenate damaged hearts by helping cardiac muscle regrow.

Conventional wisdom holds that, with the exception of skin and blood cells, most tissues in the body do not normally regenerate. But recent research has uncovered some surprising biological mechanisms that indicate that the body does in fact have the potential to repair some other vital tissues. Hoping to exploit this work, a Harvard University and University of Utah startup, Hydra BioSciences, is seeking to develop drugs that it says will repair damage from heart attacks.

Hydra’s focus is on heart attack survivors-a group joined by hundreds of thousands of people in the United States every year-who are often left with damaged, scarred cardiac tissue that could lead to complete heart failure later in life. Current drugs don’t repair the tissue, so Hydra is working on new treatments that will nudge mature heart-muscle cells to multiply again and ultimately form new, beating muscle. The three-year-old company’s first project is to develop drugs that would be given to patients within a few weeks after a heart attack to trigger regrowth of the healthy cells near the injured area and prevent the heart from weakening and scarring. A similar therapeutic strategy could eventually work for a wide range of ailments and injuries, such as type I diabetes, retinal degeneration, spinal-cord injury, and Parkinson’s disease, says Mark Keating, Hydra’s cofounder and a researcher at Children’s Hospital Boston.

In January, Hydra raised almost $19 million in second-round venture financing. And it has also made progress on discovering drug candidates. It recently isolated a protein that may stimulate cell growth in the heart and hopes to begin testing it in animals by the beginning of next year. “If this works, we can regenerate the heart and create newer, younger, better cells,” says Piero Anversa, director of the Cardiovascular Research Institute at the New York Medical College.

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.
Subscribe today

Uh oh–you've read all five of your free articles for this month.

Insider Premium

$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.

  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

You've read of free articles this month.